265 reports of this reaction
1.4% of all ICOSAPENT ETHYL reports
#15 most reported adverse reaction
ERUCTATION is the #15 most commonly reported adverse reaction for ICOSAPENT ETHYL, manufactured by Amarin Pharma Inc.. There are 265 FDA adverse event reports linking ICOSAPENT ETHYL to ERUCTATION. This represents approximately 1.4% of all 18,725 adverse event reports for this drug.
ICOSAPENT ETHYL has an overall safety score of 45 out of 100. Patients taking ICOSAPENT ETHYL who experience eructation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERUCTATION is a less commonly reported adverse event for ICOSAPENT ETHYL, but still significant enough to appear in the safety profile.
In addition to eructation, the following adverse reactions have been reported for ICOSAPENT ETHYL:
ERUCTATION has been reported as an adverse event in 265 FDA reports for ICOSAPENT ETHYL. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERUCTATION accounts for approximately 1.4% of all adverse event reports for ICOSAPENT ETHYL, making it a notable side effect.
If you experience eructation while taking ICOSAPENT ETHYL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.